NCT06617416View on ClinicalTrials.gov

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

PHASE3RecruitingINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

October 28, 2026

Study Completion Date

December 30, 2028

Conditions
NSCLC (Non-small Cell Lung Cancer)
Interventions
DRUG

Cadonilimab (AK104)

AK104 ivgtt Q3W

DRUG

Sugemalimab

1200mg Q3W

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT06617416 - A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | Biotech Hunter | Biotech Hunter